Purpose: To evaluate central serous chorioretinopathy (CSCR) by means of optical coherence tomography (OCT) and multifocal electroretinogram (mf-ERG) at presentation and after resolution of the acute phase. Design: Prospective comparative observational case series with a normal sample. Patients and Method: Twenty-one eyes of 21 patients with unilateral CSCR were examined. Both eyes underwent complete ophthalmological examination, which included measurement of best-corrected visual acuity, fluorescein angiography, OCT and mf-ERG recording. Our results were compared with the corresponding findings of 33 normal volunteers of the same age. Results: At presentation, the averaged mean retinal thickness of the fovea, measured by OCT, was 303 µm in the affected eyes, 69.3% higher compared to the normal controls (p < 0.001). The averaged mean retinal response density of the mf-ERG of the affected eyes in area 1 was 11.29 nV/degree2, 50.8% lower compared to the normal controls (p < 0.001). After regression of CSCR, the averaged mean retinal thickness of the fovea was 213 µm in the affected eyes, 19.3% greater compared to the normal controls (p < 0.001). The averaged mean retinal response density of the mf-ERG of the affected eyes in area 1 was 16.05 nV/degree2, 30.1% lower compared to normal controls (p < 0.001). It is interesting that 6 of 21 fellow nonaffected eyes showed abnormal values, with an averaged mean retinal thickness of OCT (246 µm) and an averaged mean retinal response density of mf-ERG in area 1 (12 µV/degree2). In the remaining 15 eyes, the OCT and the mf-ERG values were within normal limits.

Keywords:
Central serous chorioretinopathy, Optical coherence tomography, Multifocal electroretinogram
1.
Robertson DM: Argon laser photocoagulation treatment in central serous chorioretinopathy. Ophthalmology 1986;93:972–974.
2.
Chaine G, Houat M, Ménard-Molcard C, et al: Choriorétine séreuse centrale et corticothérapie systématique. J Fr Ophtalmol 2001;24:139–144.
3.
Jalkh AE, Jabbour N, Avia MP: Retinal pigment epithelium decompensation. I. Clinical features and natural course. Ophthalmology 1984;91:1544–1548.
4.
Brancato R, Lumbroso B: Guide to OCT Interpretation. Rome, Publisher Inc. Innovation-News-Communication, 2004, p 38.
5.
Iida T, Hagimura N, Sato T, Kishi S: Evaluation of central serous chorioretinopathy with optical coherence tomography. Am J Ophthalmol 2000;129:16–20.
6.
Hee MR, Puliafito CA, Wong C, Reichel E, Duker JS, Schuman JS, et al: Optical coherence tomography of central serous chorioretinopathy. Am J Ophthalmol 1995;120:65–74.
7.
Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA, Negrao S: Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 2003;23:1–7.
8.
Chappelow AV, Marmor MF: Multifocal electroretinogram abnormalities persist following resolution of central serous chorioretinopathy. Arch Ophthalmol 2000;118:1211–1215.
9.
Vajaranant TS, Szlyk JP, Fishman GA, Gieser JP, Seiple W: Localized retinal disfunction in central chorioretinopathy as measured using the multifocal electroretinogram. Ophthalmology 2002;109:1243–1250.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.